Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

被引：0
|
作者：
Nermine H. Zakaria
Doaa Hashad
Marwa H. Saied
Neamat Hegazy
Alyaa Elkayal
Eman Tayae
机构：
[1] University of Alexandria,Department of Clinical and Chemical Pathology, Faculty of Medicine
[2] University of Alexandria,Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine
来源：
Human Genomics | / 17卷
关键词：
HER2-positive breast cancer; Genetic variants; NGS; Trastuzumab; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
    Zakaria, Nermine H.
    Hashad, Doaa
    Saied, Marwa H.
    Hegazy, Neamat
    Elkayal, Alyaa
    Tayae, Eman
    HUMAN GENOMICS, 2023, 17 (01)
  • [2] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [3] Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
    Derakhshani, Afshin
    Rezaei, Zohreh
    Safarpour, Hossein
    Sabri, Morteza
    Mir, Atefeh
    Sanati, Mohammad Amin
    Vahidian, Fatemeh
    Moghadam, Ali Gholamiyan
    Aghadoukht, Ali
    Hajiasgharzadeh, Khalil
    Baradaran, Behzad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) : 3142 - 3156
  • [4] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [5] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
  • [6] 'Simply stunning' - trastuzumab in HER2-positive breast cancer
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) : 631 - 634
  • [7] The art of prescribing trastuzumab for HER2-positive breast cancer
    Outhoff, K.
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 3 (01) : 16 - 26
  • [8] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [9] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [10] Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
    Lameirinhas, Ana
    Torres-Ruiz, Sandra
    Garrido-Cano, Iris
    Hernando, Cristina
    Martinez, Maria Teresa
    Rovira, Ana
    Albanell, Joan
    Zazo, Sandra
    Rojo, Federico
    Bermejo, Begona
    Lluch, Ana
    Cejalvo, Juan Miguel
    Tormo, Eduardo
    Eroles, Pilar
    MOLECULAR MEDICINE, 2025, 31 (01)
12345